Over 25 Years of Clinical Experience With Ivermectin: An Overview of Safety for an Increasing Number of Indications.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing clinical experience and safety mechanisms without systematic review methods
What was done
This narrative review summarizes over 25 years of clinical experience, biological mechanisms, and safety data for ivermectin across parasitic infections and dermatological indications like rosacea.
What was found
The abstract provides no numerical data or quantitative adverse event rates. It reports qualitatively that ivermectin has low adverse event rates and a high margin of safety, attributed to high affinity for invertebrate neuronal ion channels and lack of blood-brain barrier penetration in mammals.
Why it matters
It synthesizes the safety rationale supporting the expansion of ivermectin from traditional antiparasitic use to inflammatory dermatologic conditions such as rosacea.
Limits
The abstract describes a non-systematic narrative review with no defined search protocol, no reported sample sizes (n = ?), and no quantitative safety or efficacy metrics.
Cited by
- supports Ivermectin is used as a therapeutic in humans to treat parasitic diseases, helminth infections, scabies, and lice.